Physician profile
Tekalign A Burka
NPI 1356789317
$1,862.54
in general payments reported to CMS, 2019-2025
12 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $186 · 2021: $83.93 · 2022: $36.85 · 2023: $422 · 2024: $432 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,152.41 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $290.94 | 2023-2025 | |
| Mdd US Operations, LLC | $158.37 | 2019-2020 | |
| Ucb, INC. | $58.55 | 2020-2023 | Nayzilam, Briviact |
| Allergan, INC. | $54.51 | 2019-2020 | |
| Merz North America, INC. | $32.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.15 | 2021 | |
| Corium, LLC | $24.47 | 2023 | Adlarity |
| Acorda Therapeutics, INC | $19.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.27 | 2019 | |
| Amicus Therapeutics, INC. | $11.86 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tekalign Burka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.